Cargando…

Use of health-related quality of life measures to predict health utility in postmenopausal osteoporotic women: results from the Multiple Outcomes of Raloxifene Evaluation study

BACKGROUND: The aim of this study is to examine the associations between health utility (HU), health-related quality of life (HRQoL), and patient characteristics in postmenopausal osteoporotic (PMO) women. METHODS: Baseline data from a subsample of 1,245 participants of the Multiple Outcomes of Ralo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Burge, Russel, Shen, Wei, Naegeli, April N, Alam, Jahangir, Silverman, Stuart, Gold, Deborah T, Shih, Tsehua
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4228260/ https://www.ncbi.nlm.nih.gov/pubmed/24192207 http://dx.doi.org/10.1186/1477-7525-11-189

Ejemplares similares

Psychometric properties of the osteoporosis assessment questionnaire (OPAQ) 2.0: results from the multiple outcomes of raloxifene evaluation (MORE) study
por: Shen, Wei, et al.
Publicado: (2014)

Systematic review of raloxifene in postmenopausal Japanese women with osteoporosis or low bone mass (osteopenia)
por: Fujiwara, Saeko, et al.
Publicado: (2014)

Pharmacogenomics Study for Raloxifene in Postmenopausal Female with Osteoporosis
por: Lu, Hsing-Fang, et al.
Publicado: (2020)

Denosumab Is Superior to Raloxifene in Lowering Risks of Mortality and Ischemic Stroke in Osteoporotic Women
por: Liu, Ting-Chun, et al.
Publicado: (2023)

Effect of Raloxifene Treatment on Osteocyte Apoptosis in Postmenopausal Women
por: van Essen, Huib W., et al.
Publicado: (2007)

Fractures in women treated with raloxifene or alendronate: a retrospective database analysis
por: Foster, Shonda A, et al.
Publicado: (2013)

Cost-effectiveness of bazedoxifene versus raloxifene in the treatment of postmenopausal women in Spain
por: Darbà, Josep, et al.
Publicado: (2013)

Effects of genistein aglycone in osteoporotic, ovariectomized rats: a comparison with alendronate, raloxifene and oestradiol
por: Bitto, A, et al.
Publicado: (2008)

Interpreting change from patient reported outcome (PRO) endpoints: patient global ratings of concept versus patient global ratings of change, a case study among osteoporosis patients
por: Nixon, Annabel, et al.
Publicado: (2016)

Effect of raloxifene on IGF-I and IGFBP-3 in postmenopausal women with breast cancer
por: Torrisi, R, et al.
Publicado: (2001)

Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update
por: Messalli, Enrico M, et al.
Publicado: (2010)

Effects of minodronate in postmenopausal women with osteoporosis who received prior treatment with raloxifene
por: Toda, Aska, et al.
Publicado: (2017)

Effect of follow-up raloxifene therapy after denosumab discontinuation in postmenopausal women
por: Ha, J., et al.
Publicado: (2022)

Quality of life and patient satisfaction with raloxifene/cholecalciferol combination therapy in postmenopausal women
por: Lee, Dong-Yun, et al.
Publicado: (2022)

Development of the osteoporosis assessment questionnaire—physical function (OPAQ-PF): an osteoporosis-targeted, patient-reported outcomes (PRO) measure of physical function
por: Naegeli, A. N., et al.
Publicado: (2013)

Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women
por: Tran, Oth, et al.
Publicado: (2021)

Effect of testosterone, raloxifene and estrogen replacement on the microstructure and biomechanics of metaphyseal osteoporotic bones in orchiectomized male rats
por: Stuermer, E. K., et al.
Publicado: (2009)

Modeling the Annual Costs of Postmenopausal Prevention Therapy: Raloxifene, Alendronate, or Estrogen-Progestin Therapy
por: Mullins, C. Daniel, et al.
Publicado: (2003)

The Development of the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) to Assess the Impact of Genital Psoriasis on Sexual Health
por: Gottlieb, Alice B., et al.
Publicado: (2017)

Correction to: Long-term direct and indirect economic burden associated with osteoporotic fracture in US postmenopausal women
por: Tran, Oth, et al.
Publicado: (2022)

Raloxifene inhibits the overexpression of TGF-β1 in cartilage and regulates the metabolism of subchondral bone in rats with osteoporotic osteoarthritis
por: Ping, Shao-Hua, et al.
Publicado: (2021)

Evaluation of insulin-like growth factor-I in postmenopausal women with breast cancer treated with raloxifene
por: da Silva, Benedito B, et al.
Publicado: (2007)

Comparative evaluation of raloxifene versus estrogen: Progestin on symptomatology, endometrium, and lipid profile in postmenopausal women
por: Dogiparthi, Anuradha, et al.
Publicado: (2010)

Combined treatment with dexamethasone and raloxifene totally abrogates osteoporosis and joint destruction in experimental postmenopausal arthritis
por: Islander, Ulrika, et al.
Publicado: (2011)

A randomized trial of estrogen or raloxifene during postmenopausal weight loss: Adiposity and cardiometabolic outcomes
por: Van Pelt, R.E., et al.
Publicado: (2013)

Cost-effectiveness of raloxifene in the treatment of osteoporosis in Chinese postmenopausal women: impact of medication persistence and adherence
por: Chen, Mingsheng, et al.
Publicado: (2016)

The effect of raloxifene on left ventricular hypertrophy in postmenopausal women: A prospective, randomized, and controlled study
por: Bal, Uğur Abbas, et al.
Publicado: (2015)

Raloxifene in Hemodialysis Patients
por: Keller, Frieder
Publicado: (2012)

Oxidative Stress and Raloxifene
por: Akgol, Gurkan, et al.
Publicado: (2012)

Raloxifene/Vitamin D Combination Therapy vs. Raloxifene Monotherapy on Serum 25-Hydroxy-Vitamin D Level among Postmenopausal Women with Osteoporosis or Osteopenia: A Randomized Controlled Trial
por: Lee, You-Bin, et al.
Publicado: (2022)

Co‐consuming green tea with raloxifene decreases raloxifene systemic exposure in healthy adult participants
por: Clarke, John D., et al.
Publicado: (2023)

Inflammatory response in postmenopausal osteoporotic fracture healing
por: Chow, Simon K-H., et al.
Publicado: (2020)

Audiovestibular Symptoms in Osteoporotic Postmenopausal Dominican Women
por: Acra-Tolari, Ricardo, et al.
Publicado: (2022)

Real-world health outcomes in adults with moderate-to-severe psoriasis in the United States: a population study using electronic health records to examine patient-perceived treatment effectiveness, medication use, and healthcare resource utilization
por: Armstrong, April W., et al.
Publicado: (2018)

Alendronate versus Raloxifene for Postmenopausal Women: A Meta-Analysis of Seven Head-to-Head Randomized Controlled Trials
por: Lin, Tiao, et al.
Publicado: (2014)

The Prevention of Postmenopausal Osteoporotic Fractures: Results of the Health Technology Assessment of a New Antiosteoporotic Drug
por: de Waure, Chiara, et al.
Publicado: (2014)

Inpatient cost of treating osteoporotic fractures in mainland China: a descriptive analysis
por: Yang, Yicheng, et al.
Publicado: (2015)

Safety of Raloxifene in Hemodialysis Patients
por: Jacobsen, Didy
Publicado: (2012)

Vitamin D inadequacy in Belgian postmenopausal osteoporotic women
por: Neuprez, Audrey, et al.
Publicado: (2007)

Clinical manifestations of osteoarthritis in osteoporotic and osteopenic postmenopausal women
por: Rizou, Stavroula, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4ssuo97bhmfd6ab1315s4nteu7